Multiple regression model for the association of baseline factors with gain in BCVA from baseline at months 12 and 24
| Parameter | Estimate | P value |
| Month 12 | ||
| Intercept | 37.179 | <0.0001 |
| Treatment (0.5 mg vs control) | 18.856 | <0.0001 |
| Study (ANCHOR vs MARINA) | −3.666 | 0.0059 |
| Lesion size (DA) | −1.207 | <0.0001 |
| Baseline BCVA (letters) | −0.395 | <0.0001 |
| Age (years) | −0.281 | <0.0001 |
| Month 24 | ||
| Intercept | 42.011 | <0.0001 |
| Treatment (0.5 mg vs control) | 21.156 | <0.0001 |
| Lesion size (DA) | −1.128 | <0.0001 |
| Baseline BCVA (letters) | −0.456 | <0.0001 |
| Age (years) | −0.363 | <0.0001 |
BCVA, best-corrected visual acuity; DA, disc area